GLRX

Across TCGA pan-cancer cohorts, GLRX RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of GLRX’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GLRX RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GLRX is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

KIRC, KICH, and LUSC are the cancer types where GLRX tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GLRX RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.952	<.001	12	view →
KICH	All	II,III,IV	−1.489	<.001	8	view →
LUSC	Female	All	−1.935	<.001	7	view →
LUAD	Male	All	−0.742	<.001	6	view →
KIRP	All	All	−0.556	.001	6	view →
THCA	All	II,III,IV	+0.507	.002	6	view →
READ	All	III,IV	+1.045	<.001	5	view →
BRCA	Female	All	+0.301	.002	4	view →
CHOL	All	All	−0.956	.002	2	view →
PAAD	All	All	−0.657	.018	2	view →
UCEC	All	All	+0.565	.023	2	view →
LIHC	Female	II,III,IV	−0.544	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

GLRX–KIRC

Open the KIRC breakdown →